Skip to main content

Table 1 Clinical characteristics of the patients

From: MRI-based random survival Forest model improves prediction of progression-free survival to induction chemotherapy plus concurrent Chemoradiotherapy in Locoregionally Advanced nasopharyngeal carcinoma

Variable

 

Training cohort

 

Testing cohort

 
 

Label = 0

Label = 1

P value

Label = 0

Label = 1

P value

 

N = 153

N = 53

 

N = 65

N = 23

 

Age, years

 

45.00 [34.00, 51.00]

48.00 [35.00, 52.00]

0.412

43.00 [37.00, 50.00]

45.00 [39.00, 52.50]

0.283

Height

 

1.65 [1.60, 1.70]

1.65 [1.60, 1.70]

0.674

1.65 [1.60, 1.70]

1.62 [1.54, 1.65]

0.023

Weight, kg

 

60.00 [53.00, 66.50]

59.00 [52.50, 65.00]

0.523

65.00 [57.00, 69.00]

54.00 [49.25, 61.75]

0.006

BMI

 

22.46 [20.08, 24.22]

21.97 [19.33, 24.22]

0.329

23.44 [20.90, 25.39]

21.09 [19.83, 23.66]

0.052

Follow-up Time, month

 

49.00 [37.00, 59.00]

20.00 [11.00, 33.00]

< 0.001

46.00 [37.00, 58.00]

19.00 [13.00, 24.50]

< 0.001

Sex (%)

Female

44 (28.8)

11 (20.8)

0.256

20 (30.8)

6 (26.1)

0.672

 

Male

109 (71.2)

42 (79.2)

 

45 (69.2)

17 (73.9)

 

Family (%)

No

123 (80.4)

44 (83.0)

0.674

52 (80.0)

16 (69.6)

0.305

 

Yes

30 (19.6)

9 (17.0)

 

13 (20.0)

7 (30.4)

 

Smoke (%)

No

90 (58.8)

32 (60.4)

0.843

40 (61.5)

11 (47.8)

0.252

 

Yes

63 (41.2)

21 (39.6)

 

25 (38.5)

12 (52.2)

 

EBV-DNA (%)

0

88 (57.5)

26 (49.1)

0.286

33 (50.8)

11 (47.8)

0.808

 

1

65 (42.5)

27 (50.9)

 

32 (49.2)

12 (52.2)

 

T stage (%)

T1

8 (5.2)

3 (5.7)

0.355

1 (1.5)

0 (0.0)

0.473

 

T2

38 (24.8)

8 (15.1)

 

18 (27.7)

5 (21.7)

 
 

T3

40 (26.1)

12 (22.6)

 

22 (33.8)

5 (21.7)

 
 

T4

67 (43.8)

30 (56.6)

 

24 (36.9)

13 (56.5)

 

N stage (%)

N0

3 (2.0)

0 (0.0)

0.363

1 (1.5)

0 (0.0)

0.307

 

N1

36 (23.5)

18 (34.0)

 

14 (21.5)

7 (30.4)

 
 

N2

67 (43.8)

23 (43.4)

 

23 (35.4)

11 (47.8)

 
 

N3

47 (30.7)

12 (22.6)

 

27 (41.5)

5 (21.7)

 

Overall stage (%)

3

51 (33.3)

16 (30.2)

0.674

21 (32.3)

6 (26.1)

0.578

 

4

102 (66.7)

37 (69.8)

 

44 (67.7)

17 (73.9)

 

WHO Grade (%)

I

2 (1.4)

1 (1.9)

0.422

2 (3.0)

0 (0.0)

0.558

 

II

19 (12.4)

10 (18.9)

 

6 (9.2)

0 (0.0)

 
 

III

132 (86.3)

42 (79.2)

 

57 (87.7)

23 (100.0)

 

WBC

 

7.22 [6.21, 8.76]

6.88 [5.53, 7.99]

0.079

7.17 [6.21, 8.49]

6.91 [5.70, 8.18]

0.35

Hb

 

137.00 [126.00, 150.00]

138.00 [125.00, 148.00]

0.646

140.00 [129.00, 149.00]

132.00 [119.50, 143.00]

0.072

PLT

 

272.00 [242.00, 332.00]

289.00 [231.00, 337.00]

0.934

286.00 [234.00, 335.00]

296.00 [238.00, 325.00]

0.966

NEUT

 

4.51 [3.55, 5.70]

4.39 [3.53, 5.70]

0.621

4.45 [3.60, 5.55]

3.91 [3.20, 4.94]

0.086

LYMP

 

1.87 [1.62, 2.24]

1.76 [1.42, 2.10]

0.076

1.88 [1.53, 2.32]

2.00 [1.63, 2.53]

0.403

ALB

 

0.06 (1.16)

−0.10 (0.90)

0.377

−0.11 [−0.48, 0.43]

−0.18 [−0.46, 0.29]

0.966

  1. Note: Normally distributed measurement data are presented as mean ± SD and compared by the t test; measurement data of skewed distribution are presented as M (range) and compared by the Mann-Whitney U test. Count data are presented as absolute number or percentage and compared using the χ2 test. If the chi-square test conditions are not met, the exact probability test should be used
  2. Abbreviations and definitions: Label (0, No disease progression or death from any cause; 1, First occurrence of disease progression or death from any cause); BMI Body mass index, EBV-DNA Epstein-Barr virus DNA (0, < 1000 copies/ml; 1, ≥1000 copies/ml), T Tumor, N Lymph node, WHO Grade WHO pathological subtypes of nasopharyngeal carcinoma [type I (differentiated keratinizing carcinoma), type II (differentiated non-keratinizing carcinoma), and type III (undifferentiated non-keratinizing carcinoma)], WBC White blood cell, Hb Hemoglobin, PLT Platelet, NEUT Neutrophil count, LYMP Lymphocyte count, ALB Albumin